R. Kerbel

Molecular Biology · 2000–2018

A researcher in the Science corpus: 13 papers; trusts 12 researchers and is trusted by 30 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 182 citations into it; #1,475 of 17,773 by trust here, #2,235 by citations
• Cancer Research — 89 citations into it; #390 of 1,780 by trust here, #540 by citations
• Oncology — 86 citations into it; #448 of 1,698 by trust here, #971 by citations
• Pulmonary and Respiratory Medicine — 27 citations into it; #35 of 770 by trust here, #114 by citations
• Cellular and Molecular Neuroscience — 13 citations into it
• Biotechnology — 8 citations into it
• Neurology — 8 citations into it; #551 of 1,455 by trust here, #593 by citations

Whom R. Kerbel trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. G. Klement
2. N. Ferrara
3. Rakesh K. Jain
4. P. Bőhlen
5. G. Bergers
6. D. Hanahan
7. H. Gerber
8. J. Folkman
9. D. Lyden

Who trusts R. Kerbel overall

1. N. Ferrara
2. Rakesh K. Jain
3. Nicola Bellomo
4. Peter Carmeliet
5. F. Bertolini
6. J. Folkman
7. A. Hoeben
8. Y. Shaked
9. G. Klement
10. R. Duncan

Papers from R. Kerbel's perspective

Ordered by how strongly the researchers R. Kerbel trusts endorse each paper. Same corpus, a different order for every researcher.

1. Origins of circulating endothelial cells and endothelial outgrowth from blood. (Journal of Clinical Investigation)
2. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (Nature Medicine)
3. The biology of VEGF and its receptors (Nature Medicine)
4. Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)
5. Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)
6. Tumor angiogenesis: past, present and the near future. (Carcinogenesis)
7. The present and future role of microfluidics in biomedical research (Nature)
8. A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue (Nature Protocols)
9. Innovation: Metabolomics: the apogee of the omics trilogy (Nature reviews. Molecular cell biology)
10. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. (Annual Review of Cell and Developmental Biology)

Their papers

• Clinical translation of angiogenesis inhibitors (2002) — 1,601 citations
• Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis (2009) — 1,807 citations
• The anti-angiogenic basis of metronomic chemotherapy (2004) — 1,425 citations
• The multifaceted circulating endothelial cell in cancer: towards marker and target identification (2006) — 600 citations
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000) — 610 citations
• Tumor angiogenesis: past, present and the near future. (2000) — 1,027 citations
• Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR (2009) — 667 citations
• Angiogenesis as a therapeutic target (2005) — 2,677 citations
• Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors (2006) — 602 citations
• Antiangiogenic therapy in oncology: current status and future directions. (2016) — 736 citations
• Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (2011) — 695 citations
• Consensus guidelines for the use and interpretation of angiogenesis assays (2018) — 555 citations
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (2000) — 753 citations